Presentation is loading. Please wait.

Presentation is loading. Please wait.

TRAB/2FTRAB/2O A Normal Breast Epithelium Supplemental Figure 1 iii iii iv 105 84 50 35 29 18 TRAB/2FTRAB/2O + - + - GFs B M.W. None=0<1% =11-10% =2 10-33%

Published byHester Lawrence Modified over 9 years ago

Similar presentations

Presentation on theme: "TRAB/2FTRAB/2O A Normal Breast Epithelium Supplemental Figure 1 iii iii iv 105 84 50 35 29 18 TRAB/2FTRAB/2O + - + - GFs B M.W. None=0<1% =11-10% =2 10-33%"— Presentation transcript:

1 TRAB/2FTRAB/2O A Normal Breast Epithelium Supplemental Figure 1 iii iii iv 105 84 50 35 29 18 TRAB/2FTRAB/2O + - + - GFs B M.W. None=0<1% =11-10% =2 10-33% =366-100% =533-66% =4 Negative=0Low=1 Medium=2High=3 Frequency of Elafin-Positive Cells Staining Intensity of Elafin-Positive Cells C D

2 B Basal-like HER2+ Luminal A Luminal B Normal TCGA Breast p=0.0015 p<0.0001 Log 2 -mean centered values PAM50 Normal Luminal B Luminal A Basal HER2 PI3 (Elafin) TCGA Breast Supplemental Figure 2A -2 2 Log 2 -Median Centered

3 FactorsElafin Negative (n=171)Positive (n=42)p-value Age at diagnosis, year 0.09 Mean57.559.6 Median (range)58 (20-83)63 (27-87) Histological Type 0.7 Serous125 (73.1)32 (76.2) Endometroid19 (11.1)2 (4.8) Clear Cell8 (4.7)1 (2.4) Transitional Cell4 (2.3)2 (4.8) Malignant Mixed Müllerian7 (4.0)1 (2.4) Undifferentiated7 (4.0)2 (4.8) Others1 (0.6)2 (4.8) FIGO stage 0.006 I/II33 (19.3)3 (7.2) III/IV138 (80.8)39 (92.8) Grade 0.5 Low15 (8.8)2 (4.8) High156 (91.2)40 (95.2) Ascites Level 0.05 No18 (15)1 (2.5) Yes102 (85)39 (97.5) Unknown512 Response to treatment 0.02 No24 (15)12 (30.8) Yes136 (85)27 (69.2) Unknown113 Serum CA 125 level 0.018 <500 U/mL43 (45.3)6 (20) >500 U/mL52 (54.7)24 (80) Unknown7612 Univariate analysis ovarian cancer (n=213) Supplemental Table 1 Factor HRSeP95% CI Stage I/IIReferent III/IV3.431.390.0021.55 Elafin Positive0.930.210.70.60 Ascites2.771.210.021.18 Response to treatment0.150.04<0.00010.09 Multivariate Cox Proportional Hazards Analysis of Clinicopathologic Variables’ Influence on Ovarian Cancer Disease-Specific Survival (DSS) in whole cohort (n=213) A B

Download ppt "TRAB/2FTRAB/2O A Normal Breast Epithelium Supplemental Figure 1 iii iii iv 105 84 50 35 29 18 TRAB/2FTRAB/2O + - + - GFs B M.W. None=0<1% =11-10% =2 10-33%"

Similar presentations

Hereditary ovarian/breast cancers (HOC/HBOC) Chair and Department of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents. Head: Prof.

Hereditary ovarian/breast cancers (HOC/HBOC) Chair and Department of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents. Head: Prof.
Ji Young Lee, MD, PhD, David Marchetti, MD, M Steven Piver, MD Department of Obstetrics and Gynecology Sisters of Charity Hospital, Buffalo, NY The Clinical.

Ji Young Lee, MD, PhD, David Marchetti, MD, M Steven Piver, MD Department of Obstetrics and Gynecology Sisters of Charity Hospital, Buffalo, NY The Clinical.
Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.
Genetic and Molecular Epidemiology

Genetic and Molecular Epidemiology
Ovarian Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”

Ovarian Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”
5 15 25 20 10 Ct value Log concentration miR-375 miR-221 Supplementary Figure S1.

Ct value Log concentration miR-375 miR-221 Supplementary Figure S1.
Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases J.M. Escudero,

Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases J.M. Escudero,
4% of all female cancers 25% of all gynecologic cancers life time risk: 1/70 ¾ advanced stage most lethal Epithelial Ovarian Cancer:

4% of all female cancers 25% of all gynecologic cancers life time risk: 1/70 ¾ advanced stage most lethal Epithelial Ovarian Cancer:
Vitamin D Deficiency is Common at Breast Cancer Diagnosis and is Associated with a Significantly Higher Risk of Distant Recurrence and Death in a Prospective.

Vitamin D Deficiency is Common at Breast Cancer Diagnosis and is Associated with a Significantly Higher Risk of Distant Recurrence and Death in a Prospective.
Comparing the Positive Effect of Vitamin E and Flouxetine in the Treatment of Hot Flashes in Breast Cancer Patients. Comparing the Positive Effect of.

Comparing the Positive Effect of Vitamin E and Flouxetine in the Treatment of Hot Flashes in Breast Cancer Patients. Comparing the Positive Effect of.
Lymphadenectomy in Epithelial Ovarian Cancer

Lymphadenectomy in Epithelial Ovarian Cancer
Management and Development for Health (MDH)

Management and Development for Health (MDH)
Black Patients Die Earlier after Surgery for Esophageal Cancer Andrea S. Wolf, MD, MPH, Emanuela Taioli MD, PhD, Marlene Camacho-Rivera, ScD, MPH, Andrew.

Black Patients Die Earlier after Surgery for Esophageal Cancer Andrea S. Wolf, MD, MPH, Emanuela Taioli MD, PhD, Marlene Camacho-Rivera, ScD, MPH, Andrew.
PANCREATIC CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY 2009.

PANCREATIC CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY 2009.
Romero IL, McCormick A, McEwen et al. 2012. Obstetrics & Gynecology, vol. 119:61-67.

Romero IL, McCormick A, McEwen et al Obstetrics & Gynecology, vol. 119:61-67.
Tumors Dr. N. Salmo. Adrenal cortical tumor. Describe it grossly. Benign or Malignant??

Tumors Dr. N. Salmo. Adrenal cortical tumor. Describe it grossly. Benign or Malignant??
Conclusion IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION (ANATOLIAN.

Conclusion IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION (ANATOLIAN.
Investigation of CA9 expression in pulmonary metastatic lesions from patients with clear cell renal cell carcinoma Pierre Tennstedt 1, Peter Schneider.

Investigation of CA9 expression in pulmonary metastatic lesions from patients with clear cell renal cell carcinoma Pierre Tennstedt 1, Peter Schneider.
Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma.

Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma.
Supplementary table 1 Supplementary table 1. Clinical-pathological features of the resection-only and chemotherapy/resection stage II/III colorectal cancer.

Supplementary table 1 Supplementary table 1. Clinical-pathological features of the resection-only and chemotherapy/resection stage II/III colorectal cancer.

Similar presentations

Ads by Google